ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of gastric cancer
Open Access
- 1 May 2005
- journal article
- guideline
- Published by Elsevier in Annals of Oncology
- Vol. 16 (suppl_1) , i22-i23
- https://doi.org/10.1093/annonc/mdi812
Abstract
1Invited author, The Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK; 2Invited author and member of the task force, Oncology, Kantonsspital, CH-4101 Bruderholz/BL, Switzerland; 3Assigned task force member, P. Stradins University Hospital, Radiation & Chemotherapy Center, Pilsonu Str. 13, Riga, LV 1002, Latvia; 4Assigned task force member, Instituto Português de Oncologia Francisco Gentil, R. Prof. Lima Basto, 1099–023 Lisboa, PortugalKeywords
This publication has 7 references indexed in Scilit:
- Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trialAnnals of Oncology, 2004
- 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere®)–cisplatin in advanced gastric carcinoma: a phase I–II trialAnnals of Oncology, 2004
- Phase II Trial of Capecitabine/Irinotecan and Capecitabine/Oxaliplatin in Advanced Gastrointestinal CancersClinical Colorectal Cancer, 2004
- Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal JunctionNew England Journal of Medicine, 2001
- A Systematic Overview of Chemotherapy Effects in Gastric CancerActa Oncologica, 2001
- Current status and future perspectives in gastric cancer managementCancer Treatment Reviews, 2000
- Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.Journal of Clinical Oncology, 1997